Cardinal Health Earnings: Can Perfection Get Priced In Twice?

Cardinal Health (CAH) saw its stock hit a new all-time high despite mixed Q4 fiscal year results, including a revenue miss and a decline in its Global Medical Products and Distribution unit. The company's growth is being driven by its high-margin cell-and-gene-therapy logistics business, which now exclusively serves nearly half of that market, projected to reach $106 billion by 2033. Analysts have raised price targets, and Cardinal Health maintains a 29-year streak of dividend increases, indicating continued investor confidence despite valuation concerns.